These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38921182)

  • 21. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
    Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
    Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis.
    Du J; Han X; Lin S; Qiu C; Zhu L; Huang Z; Hou J
    Front Med (Lausanne); 2021; 8():732727. PubMed ID: 34805202
    [No Abstract]   [Full Text] [Related]  

  • 23. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma.
    Nachmias B; Shaulov A; Lavie D; Goldschmidt N; Gural A; Saban R; Lebel E; Gatt ME
    Acta Haematol; 2019; 141(4):216-221. PubMed ID: 30943470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
    Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
    Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
    Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Hosing C; Nieto YL; Oki Y
    Br J Haematol; 2017 Mar; 176(5):750-758. PubMed ID: 27983760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
    Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving gastrointestinal quality of life: romidepsin to tucidinostat in a case of angioimmunoblastic T cell lymphoma.
    Isoda A; Terasaki Y; Kanaya S; Saito A
    BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38199657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Romidepsin (Istodax
    Ro T; Nakayama N; Achiwa H; Ohtsu T
    Nihon Yakurigaku Zasshi; 2018; 151(3):122-129. PubMed ID: 29526921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
    Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
    Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.
    Bennani NN; Kim HJ; Pederson LD; Atherton PJ; Micallef IN; Thanarajasingam G; Nowakowski GS; Witzig T; Feldman AL; Ansell SM
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35750419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
    Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F
    Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant.
    Chiu M; Hague S; Elinder-Camburn A; Merriman E; Chan H
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):835-840. PubMed ID: 35915036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
    Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
    Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
    Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
    Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study
    Skamene T; Crump M; Savage KJ; Reiman T; Kuruvilla J; Good D; LeBrun D; Meyer RM; Sehn LH; Soulières D; Stakiw J; Laferriere N; Luminari S; Shepherd LE; Djurfeldt M; Zhu L; Chen BE; Hay AE
    Leuk Lymphoma; 2017 Oct; 58(10):2319-2327. PubMed ID: 28504033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.
    Ruan J; Zain J; Palmer B; Jovanovic B; Mi X; Swaroop A; Winter JN; Gordon LI; Karmali R; Moreira J; Petrich AM; Pro B
    Blood Adv; 2023 Oct; 7(19):5771-5779. PubMed ID: 37327113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.